Bi-ancestral depression GWAS in the Million Veteran Program and meta-analysis in >1.2 million individuals highlight new therapeutic directions
- PMID: 34045744
- PMCID: PMC8404304
- DOI: 10.1038/s41593-021-00860-2
Bi-ancestral depression GWAS in the Million Veteran Program and meta-analysis in >1.2 million individuals highlight new therapeutic directions
Abstract
Major depressive disorder is the most common neuropsychiatric disorder, affecting 11% of veterans. Here we report results of a large meta-analysis of depression using data from the Million Veteran Program, 23andMe, UK Biobank and FinnGen, including individuals of European ancestry (n = 1,154,267; 340,591 cases) and African ancestry (n = 59,600; 25,843 cases). Transcriptome-wide association study analyses revealed significant associations with expression of NEGR1 in the hypothalamus and DRD2 in the nucleus accumbens, among others. We fine-mapped 178 genomic risk loci, and we identified likely pathogenicity in these variants and overlapping gene expression for 17 genes from our transcriptome-wide association study, including TRAF3. Finally, we were able to show substantial replications of our findings in a large independent cohort (n = 1,342,778) provided by 23andMe. This study sheds light on the genetic architecture of depression and provides new insight into the interrelatedness of complex psychiatric traits.
Conflict of interest statement
Conflict of Interest
Dr. Stein reports receiving consulting fees in the past 3 years from Acadia Pharmaceuticals, Aptinyx, Bionomics, Clexio Biosciences, EmpowerPharm, Genentech/Roche, GW Pharmaceuticals, Janssen, Jazz Pharmaceuticals, and Oxeia Biopharmaceuticals.
In the last 12 months Dr. Sanacora has provided consulting services to Allergan, Axsome Therapeutics, Biohaven Pharmaceuticals, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Clexio Biosciences, Epiodyne, Intra-Cellular Therapies, Janssen, Lundbeck, Minerva pharmaceuticals, Navitor Pharmaceuticals, NeuroRX, Noven Pharmaceuticals, Otsuka, Perception Neuroscience, Praxis Seelos Pharmaceuticals and Vistagen Therapeutics. He has received funds for contracted research from Janssen Pharmaceuticals, Merck, and Usona Institute. He holds equity in Biohaven Pharmaceuticals and has received royalties from Yale University paid from patent licenses with Biohaven Pharmaceuticals.
Jingchunzi Shi and Suyash Shringarpure are employed by and hold stock or stock options in 23andMe, Inc.
Dr. Gelernter is named as co-inventor on PCT patent application #15/878,640 entitled: “Genotype-guided dosing of opioid agonists,” filed January 24, 2018.
All other authors declare that they have no conflict of interest. No other conflicts are reported.
Figures





Similar articles
-
Identification of Novel, Replicable Genetic Risk Loci for Suicidal Thoughts and Behaviors Among US Military Veterans.JAMA Psychiatry. 2023 Feb 1;80(2):135-145. doi: 10.1001/jamapsychiatry.2022.3896. JAMA Psychiatry. 2023. PMID: 36515925 Free PMC article.
-
Genome-wide association study of traumatic brain injury in U.S. military veterans enrolled in the VA million veteran program.Mol Psychiatry. 2024 Jan;29(1):97-111. doi: 10.1038/s41380-023-02304-8. Epub 2023 Oct 24. Mol Psychiatry. 2024. PMID: 37875548
-
Genome-wide analyses reveal novel opioid use disorder loci and genetic overlap with schizophrenia, bipolar disorder, and major depression.Addict Biol. 2023 Jun;28(6):e13282. doi: 10.1111/adb.13282. Addict Biol. 2023. PMID: 37252880 Free PMC article.
-
Interpretation of risk loci from genome-wide association studies of Alzheimer's disease.Lancet Neurol. 2020 Apr;19(4):326-335. doi: 10.1016/S1474-4422(19)30435-1. Epub 2020 Jan 24. Lancet Neurol. 2020. PMID: 31986256 Free PMC article. Review.
-
Identification of novel risk loci for restless legs syndrome in genome-wide association studies in individuals of European ancestry: a meta-analysis.Lancet Neurol. 2017 Nov;16(11):898-907. doi: 10.1016/S1474-4422(17)30327-7. Lancet Neurol. 2017. PMID: 29029846 Free PMC article. Review.
Cited by
-
The genetic contribution to the comorbidity of depression and anxiety: a multi-site electronic health records study of almost 178 000 people.Psychol Med. 2023 Nov;53(15):7368-7374. doi: 10.1017/S0033291723000983. Epub 2023 May 5. Psychol Med. 2023. PMID: 38078748 Free PMC article.
-
INviting Veterans InTo Enrollment in Alzheimer's Disease Research Centers (INVITE-ADRC): An NIA and VA-sponsored initiative to increase veteran participation in aging and dementia research.Alzheimers Dement. 2024 Apr;20(4):3088-3098. doi: 10.1002/alz.13725. Epub 2024 Feb 13. Alzheimers Dement. 2024. PMID: 38348782 Free PMC article.
-
Independent Associated SNPs at SORCS3 and Its Protein Interactors for Multiple Brain-Related Disorders and Traits.Genes (Basel). 2023 Feb 14;14(2):482. doi: 10.3390/genes14020482. Genes (Basel). 2023. PMID: 36833409 Free PMC article.
-
Feasibility and application of polygenic score analysis to the morphology of human-induced pluripotent stem cells.Mol Genet Genomics. 2022 Jul;297(4):1111-1122. doi: 10.1007/s00438-022-01905-2. Epub 2022 May 28. Mol Genet Genomics. 2022. PMID: 35633379 Free PMC article.
-
Body mass index and inflammation in depression and treatment-resistant depression: a Mendelian randomisation study.BMC Med. 2023 Sep 14;21(1):355. doi: 10.1186/s12916-023-03001-7. BMC Med. 2023. PMID: 37710313 Free PMC article.
References
-
- Roehrig C. Mental Disorders Top The List Of The Most Costly Conditions In The United States: $201 Billion. Health Affairs 35, 1130–1135 (2016). - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials